SPARC and prostate carcinoma: However, an opposite correlation has also been demonstrated, suggesting that SPARC may be able to inhibit tumorigenesis or tumor progression in breast cancer [15], [16], hepatocellular carcinoma [17], prostate cancer [18], colorectal cancer [19], [20], and ovarian cancer [21].